Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, has appointed Juan Carlos Jaramillo, MD as chief medical officer and member of the Management Board starting October 1, 2020. Jaramillo will succeed Wolfgang Bender, MD, PhD who will retire after a hand-over period, at the end of October 2020.
 
Jaramillo has broad international experience and strong expertise in medical affairs and clinical development, including vaccines. Due to his diverse pharma exposure, he has an in-depth business understanding and a track-record of success across a wide range of settings, therapeutic areas and geographies. He has worked in various pharmaceutical/biotech organizations, including GlaxoSmithKline, Grünenthal and Daiichi Sankyo.
 
“I am delighted to be joining Valneva at an extremely exciting time. Valneva has a great and valuable portfolio of vaccines in development including chikungunya, Lyme and SARS-COV-2. I’m looking forward to be part of the Valneva team, working on these important programs and joining the Management Board,” commented Jaramillo.
 
Thomas Lingelbach, CEO of Valneva, said, “We are thrilled that Juan Carlos is joining Valneva. His expertise and multi-cultural leadership skills will be a great addition to the company.”